BioSpace News Archive

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of pre-clinical data for three pipeline programs in oral and poster sessions at the upcoming AACR-NCI-EORTC Virtual International Conference.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, announced positive data from Part A of its Phase 2 study of THR-149, a plasma kallikrein inhibitor, for the treatment of DME.

CytoReason and Summit Pharmaceuticals International announced that CytoReason has entered the Japanese market, with its technology being utilized by one of Japan’s top pharmaceutical companies.

Valbiotis, a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, publishes its financial report for the first half of 2021 and provides an update on the Company’s progress.

Targovax ASA announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax’s Chemistry, Manufacturing, and Controls program forward.

Steerable robotic catheters are minimally invasive medical devices that have wide application in cardiac surgery, vascular surgery, neurosurgery, orthopedic surgery, gastrointestinal surgery, and uterine surgery. Steerable robotic catheters are manipulated by a mechanism, which may be driven by operators or actuators.

Photo rejuvenation is another form of facial rejuvenation that utilizes broad wavelength light that is absorbed by brown and red pigments present under the skin.

The demand within the global nasal oxygen cannula market is growing at a sound pace in recent times. The rising incidence of respiratory disorders has created new opportunities for growth within the global nasal oxygen cannula market.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a report published by Fact.MR, the global wireless handheld ultrasound devices market is poised to total US$ 666 million by the end of 2021.

Hemogenyx Pharmaceuticals plc, the StandardListed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2021.